• Users Online: 1015
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 5  |  Issue : 3  |  Page : 178-182

“Super” high-frequency subthalamic stimulation for managing refractory dyskinesia in Parkinson’s disease


1 Department of Neurology, Prasat Neurological Institute, Bangkok, Thailand; Department of Neurology, Juntendo University School of Medicine, Bunkyo City, Tokyo
2 Department of Neurology, Juntendo University School of Medicine, Bunkyo City, Tokyo; Department of Neurodegenerative and Demented Disorders, Juntendo University Graduate School of Medicine, Tokyo, Japan; Home Medical Care System, based on Information and Communication Technology, Juntendo University Graduate School of Medicine, Tokyo, Japan; Drug Development for Parkinson’s Disease, Juntendo University Graduate School of Medicine, Tokyo, Japan; PRO-Based Integrated Data Analysis in Neurological Disorders, Juntendo University Graduate School of Medicine, Tokyo, Japan; Research and Therapeutics for Movement Disorders, Juntendo University Graduate School of Medicine, Tokyo, Japan
3 Department of Neurology, Juntendo University School of Medicine, Bunkyo City, Tokyo
4 Department of Neurosurgery, Juntendo University School of Medicine, Bunkyo City, Tokyo; Research and Therapeutics for Movement Disorders, Juntendo University Graduate School of Medicine, Tokyo, Japan

Correspondence Address:
Genko Oyama
Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113–8421
Japan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/AOMD.AOMD_11_22

Rights and Permissions

Objective: To evaluate and compare the effect of “super” high-frequency (SHF; >130 Hz) stimulation and conventional high-frequency (CHF; 100–130 Hz) stimulation on patients with dyskinesia. Methods: The patients were evaluated using the Abnormal Involuntary Movement Scale (AIMS) with SHF and CHF after levodopa infusion. The secondary outcomes included the Burke–Fahn–Marsden dystonia rating scale and the Unified Parkinson’s Disease Rating Scale part III scores. Result: Six patients were enrolled in this study. The AIMS scores were not significantly different between SHF and CHF (p=0.89, paired t-test). Three out of six patients (50%) had better AIMS scores when SHF was applied, the scores of two patients remained unchanged, and one patient had a score worse than that with CHF. No short-term adverse effects were observed. Conclusion: The results of our pilot study show that SHF is safe and tolerable. We believe that in appropriate cases SHF can be used for managing dyskinesia after conventional methods yield unfavorable results.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed961    
    Printed88    
    Emailed0    
    PDF Downloaded92    
    Comments [Add]    

Recommend this journal